CNJ.TO  Cangene Cp




Life Sciences


Market Cap.


Vuru Grade


Current Price

0.00 (0.00%)

Growth Price

Undervalued by 25.65%

Stability Price

Overvalued by 39.67%

Company Metrics

  • P/E 169
  • P/S 2.08
  • P/B 1.25
  • EPS -0.15
  • Cash ROIC 5.13%
  • Cash Ratio 1.47
  • Dividend 0 / 0%
  • Avg. Vol. 255,197.00
  • Shares 66.75M
  • Market Cap. 240.3M

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire (press release) - Feb 21, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects ...
Cangene Announces Completion of Acquisition by Emergent BioSolutions - Canada NewsWire (press release)
Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.
Washington Post - Dec 11, 2013
Emergent BioSolutions established itself as a leading biodefense company by selling Anthrax vaccines en masse to the federal government in the wake of Sept.
Emergent BioSolutions strikes $222M deal to buy Cangene Corp. - Baltimore Sun
Cangene bought by US rival for $236-million, latest Canadian biotech taken private - The Globe and Mail
PR Newswire (press release) - May 2, 2011
BALTIMORE AND WINNIPEG, May 2 /PRNewswire/ - Cangene Corporation's Baltimore-based injectable pharmaceutical contract-manufacturing subsidiary, Cangene bioPharma, Inc., has completed a US$11-million renovation of its sterile filling and support ...
Cangene takeover might not be a bad thing
Winnipeg Free Press - Dec 20, 2013
The recently announced proposed sale of Cangene Corp. to Emergent BioSolutions Inc. of Maryland for $222 million is bringing up those concerns once again.
Cangene To Be Acquired By Emergent BioSolutions For US$222 Million
Canada NewsWire (press release) - Dec 11, 2013
11, 2013 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE: EBS) of Rockville, Maryland will acquire Cangene in an all-cash transaction ...
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale ...
Business Wire (press release) - Feb 20, 2013
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Inspiration Biopharmaceuticals Inc. (Inspiration) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene).
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene -
Cangene Inks $300+M Deal for Bankrupt Inspiration's IB1001 - Genetic Engineering News
Cangene acquires Twinstrand Therapeutics Inc.
Canada NewsWire (press release) - Jul 7, 2009
Listed TSX, Symbol: CNJ TORONTO and WINNIPEG, July 7 /CNW/ - Cangene Corporation today announces that it has acquired all issued and outstanding shares of privately held Twinstrand Therapeutics Inc. ("Twinstrand").
FDA lifts clinical hold on Cangene's hemophilia compound IB1001
Canada NewsWire (press release) - Jul 29, 2013
WINNIPEG, July 29, 2013 /CNW/ - Cangene Corporation (Cangene) today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on clinical trials evaluating the safety and efficacy of IB1001, a recombinant ...
Cangene Appoints New Chief Financial Officer
Canada NewsWire (press release) - Jun 15, 2012
WINNIPEG, June 15, 2012 /CNW/ - Cangene Corporation, a biopharmaceutical company primarily focused on hospital based therapeutics, today announces that it has appointed Mr. Jeff Lamothe as its new Chief Financial Officer, to be effective August 1, ...
Company Shares of Emergent Biosolutions, Inc. (NYSE:EBS) Drops by -1.94%
American Trade Journal - Oct 4, 2015
Emergent Biosolutions, Inc. (NYSE:EBS) has lost 1.94% during the past week and dropped 11.17% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.94%.